SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION

摘要

GPC Biotech AG (Frankfurt Stock Exchange:GPC;TecDAX index;NASDAQ:GPCB) and Pharmion Corporation (NASDAQ:PHRM) have announced that final progression-free survival (PFS) results for the double-blind,randomized satraplatin Phase 3 registrational trial,the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) were presented recently at the ASCO Prostate Cancer Symposium.The trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone- refractory prostate cancer (HRPC) who have failed prior chemotherapy.All analyses of PFS being presented were conducted on an intent-to- treat basis.